Alina Zorn is PhD Student at the University of Glasgow, Scotland. Her research is primarily focused on developing protein-degrading drugs (PROTACS) for the treatment of cancer and neurodegenerative disease.
Alina is a two-time graduate of the University of Aberdeen with a degree in Biomedical Sciences (Pharmacology & Biobusiness) and an MSci by Research in Medical Sciences.